mesdopetam
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 8, 2016 (NCT03531060)
Timeline
Indications
Studied for
Mechanism of action
- Dopamine D3 receptorANTAGONIST
DRD3 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCCNCCOc1cc(F)cc(S(C)(=O)=O)c1- Mol. weight
- 275.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594447 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04435431 | Phase 2 | Sep 30, 2020 | Integrative Research Laboratories AB |
| NCT03368170 | Phase 2 | Feb 27, 2018 | Integrative Research Laboratories AB, The Clinical Trial Company, University of Plymouth |
| NCT03531060 | Phase 1/Phase 2 (Phase 2) | Nov 8, 2016 | Integrative Research Laboratories AB, Karolinska Institute |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Integrative Research Laboratories AB | For profit | 3 | 3 | 1 | 2016 |
| Karolinska Institute | Academic/Hospital | 1 | 0 | 1 | 2016 |
| The Clinical Trial Company | For profit | 1 | 0 | 1 | 2018 |
| University of Plymouth | Academic/Hospital | 1 | 0 | 1 | 2018 |
4 organizations
Page 1 / 1